

EXHIBIT 108

Highly Confidential - Subject to Further Confidentiality Review

Page 1

UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OHIO
EASTERN DIVISION

IN RE: NATIONAL)	
PRESCRIPTION)	MDL No. 2804
OPIATE LITIGATION)	
_____)	Case No.
)	1:17-MD-2804
)	
THIS DOCUMENT RELATES)	Hon. Dan A.
TO ALL CASES)	Polster

THURSDAY, NOVEMBER 8, 2018

HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
CONFIDENTIALITY REVIEW

- - -

Videotaped deposition of Steven
Mills, held at the offices of BARTLIT BECK
HERMAN PALENCHAR & SCOTT LLP, 54 West
Hubbard, Suite 300, Chicago, Illinois,
commencing at 9:07 a.m., on the above date,
before Carrie A. Campbell, Registered
Diplomate Reporter and Certified Realtime
Reporter.

- - -

GOLKOW LITIGATION SERVICES
877.370.3377 ph | 917.591.5672 fax
deps@golkow.com

Highly Confidential - Subject to Further Confidentiality Review

Page 10	Page 12
<p>1 MR. ERB: And this is Chip Erb 2 with Cavitch, Familo & Durkin 3 representing Discount Drug Mart. 4 MR. WEEKS: Paul Weeks for 5 Allergan Finance. 6 MS. KLOCKENGA: Jodi Klockenga 7 with Napoli Shkolnik. 8 MS. MITCHELL: Wendy Mitchell 9 with Napoli Shkolnik. 10 11 STEVEN MILLS, 12 of lawful age, having been first duly sworn 13 to tell the truth, the whole truth and 14 nothing but the truth, deposes and says on 15 behalf of the Plaintiffs, as follows: 16 17 DIRECT EXAMINATION 18 QUESTIONS BY MR. SHKOLNIK: 19 Q. Mr. Mills, my name is Hunter 20 Shkolnik. I'm going to be asking you a 21 series of questions here today, but anytime 22 you don't understand me, please let me know. 23 I have a tendency to sometimes 24 talk fast. Usually by the time it starts 25 affecting you, the court reporter usually</p>	<p>1 epidemic developing in the United States? 2 A. I have an understanding, yes. 3 Q. When did you first become aware 4 that there was an opioid epidemic developing 5 in the United States? 6 MR. HILL: Object to the form. 7 THE WITNESS: 2012. 8 QUESTIONS BY MR. SHKOLNIK: 9 Q. So what happened in 2012 that 10 made you come to a realization that there was 11 an opioid epidemic in the United States? 12 A. There was a creation of the RX 13 integrity team, which I'm currently a member 14 of. 15 Q. And prior to 2012, were you 16 involved in any capacity with prescription 17 integrity at Walgreens? 18 MR. HILL: Object to the form. 19 THE WITNESS: No. 20 QUESTIONS BY MR. SHKOLNIK: 21 Q. Was prescription integrity a 22 new department that was developed at some 23 point in time at Walgreens while you were 24 there? 25 A. Yes.</p>
Page 11	Page 13
<p>1 throws something at me and stops me. But if 2 at any time I start going too fast, just tell 3 me to slow down. 4 If you don't understand a 5 question, let me know. I try my best, but 6 every once in a while I do ask a bad 7 question. So if you don't understand it, 8 just say. I'll rephrase the question. 9 Okay? 10 A. Okay. 11 Q. And whenever there's a 12 question, it has to be a verbal answer. A 13 nod doesn't -- doesn't help. May show up on 14 the video but not on the transcript. 15 Okay? 16 A. Got it. 17 Q. Sir, you work for Walgreens at 18 the current time? 19 A. I do. 20 Q. And how long have you worked 21 for Walgreens? 22 A. The past 13 years. 23 Q. So over the 13 years you've 24 been working at Walgreens, do you have an 25 understanding that there was an opioid</p>	<p>1 Q. So before the company developed 2 prescription integrity department -- withdraw 3 that. 4 Was it called the prescription 5 integrity department? 6 A. Pharmaceutical integrity. 7 Q. Okay. Pharmaceutical integrity 8 department. 9 Prior to the development of the 10 pharmaceutical integrity department at 11 Walgreens in 2012, was there any other 12 department in existence at Walgreens that had 13 the same responsibilities as the now new 14 pharmaceutical integrity group -- 15 MR. HILL: Object to the form. 16 QUESTIONS BY MR. SHKOLNIK: 17 Q. -- or department? 18 A. I don't know. 19 Q. Did you do anything prior to 20 2012 in terms of pharmaceutical -- 21 pharmaceutical integrity work, the type 22 you're doing after 2012 prior to 2012? 23 A. No. 24 Q. What type of work did you do 25 before 2012?</p>

4 (Pages 10 to 13)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 14</p> <p>1 A. Prior to 2012, I was working in 2 the pharmacy inventory group where we manage 3 item vendor catalog setup so our stores can 4 order product accordingly. If the item's not 5 set up, then our stores don't have the 6 ability to order it per our ordering system. 7 Q. Was there any specific aspect 8 of that job that dealt with opioids or 9 Class II, Class III pharmaceuticals? 10 A. Can you rephrase your question? 11 Q. Sure. 12 Was any aspect of your job 13 prior to 2012 dealing with the distribution 14 of opioids? 15 A. To answer your question, yes, I 16 would be responsible for setting up items to 17 be available for ordering through our catalog 18 for opioids, C-II, C-III. I believe that's 19 what you're asking. 20 Q. Okay. Tell me what you did 21 with respect to setting up and cataloging of 22 opioid, C-II, C-III, drugs prior to 2012. 23 A. So it would be logging into a 24 computer system, to a web UI, setting up the 25 NDC codes, setting up the UPC numbers and</p>	<p style="text-align: right;">Page 16</p> <p>1 Q. Like the co-op programs they 2 had back then? 3 A. I didn't take advantage of any 4 programs. 5 Q. So you've been with Walgreens 6 ever since Northeastern up until the present 7 time? 8 A. Yes. 9 Q. Now, going back to the issue of 10 opioid epidemic, tell me what it was that 11 triggered in your mind that 2012 there was an 12 opioid epidemic in the United States. 13 MR. HILL: Object to the form. 14 THE WITNESS: Due to the 15 information that was available around 16 the DEA visits to our Jupiter DCs 17 around opioid dispensing. 18 QUESTIONS BY MR. SHKOLNIK: 19 Q. And other than the fact that 20 the DEA came down on Walgreens through its 21 Jupiter distribution facility, you had not 22 been aware that there was a problem with 23 opioids in the United States and it was at 24 epidemic level before that? 25 MR. HILL: Object to the form.</p>
<p style="text-align: right;">Page 15</p> <p>1 then loading that into our ordering system so 2 stores would be able to get replenishment. 3 Q. So it was a job that focused 4 more on the logistics aspect of the 5 pharmaceutical side of the company or just -- 6 withdraw that. 7 So was your job dealing more 8 with logistics, making sure that product was 9 available and product could be shipped? 10 A. Nothing to do with product 11 availability. 12 Q. Okay. 13 A. It was more data entry and item 14 maintenance. 15 Q. What is your background in 16 terms of education, sir? 17 A. Communications degree from 18 Northeastern University. 19 Q. And when you were at 20 Northeastern, did you work for Walgreens as 21 part of any of the -- they have the work 22 study programs there. Did you start with 23 Walgreens back then? 24 A. I started with Walgreens while 25 I was in college, yes.</p>	<p style="text-align: right;">Page 17</p> <p>1 Assumes facts. 2 THE WITNESS: I don't know. It 3 wasn't part of my job responsibilities 4 prior. 5 QUESTIONS BY MR. SHKOLNIK: 6 Q. Well, I mean, did people talk 7 about it at Walgreens prior to 2012, there's 8 an opioid problem in the United States? 9 MR. HILL: Object to the form. 10 THE WITNESS: I can't remember. 11 QUESTIONS BY MR. SHKOLNIK: 12 Q. Did you know any people that 13 had suffered from the ill effects of opioids 14 prior to 2012? 15 A. No. 16 Q. Prior to 2012, to your 17 knowledge, did -- withdraw that. 18 Part of your job is suspicious 19 order monitoring work; am I correct? 20 MR. HILL: Object to the form. 21 THE WITNESS: That is a part of 22 my job, yes. 23 QUESTIONS BY MR. SHKOLNIK: 24 Q. Prior to 2012, had you ever 25 heard of the phrase "suspicious order</p>

5 (Pages 14 to 17)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 170</p> <p>1 approved, someone in charge of inventory, the</p> <p>2 sales inventory of the company, was approving</p> <p>3 the bonuses for the sale of controlled</p> <p>4 substance pills at the pharmacy level; fair</p> <p>5 statement?</p> <p>6 MR. HILL: Same objections, and</p> <p>7 asked and answered.</p> <p>8 THE WITNESS: I don't know.</p> <p>9 QUESTIONS BY MR. SHKOLNIK:</p> <p>10 Q. Do you think it's right for a</p> <p>11 pharmacist to get a bonus based on how many</p> <p>12 opioid pills they distribute?</p> <p>13 MR. HILL: Object to the form.</p> <p>14 THE WITNESS: I don't know.</p> <p>15 QUESTIONS BY MR. SHKOLNIK:</p> <p>16 Q. And you wouldn't like -- you</p> <p>17 don't approve of that yourself, do you?</p> <p>18 MR. HILL: Same objections.</p> <p>19 QUESTIONS BY MR. SHKOLNIK:</p> <p>20 Q. Forget about Walgreens.</p> <p>21 Yourself.</p> <p>22 Do you approve of the fact that</p> <p>23 a pharmacist would get a bonus on how many</p> <p>24 opioid pills they sell?</p> <p>25 MR. HILL: Same objections.</p>	<p style="text-align: right;">Page 172</p> <p>1 MR. HILL: Same objections.</p> <p>2 THE WITNESS: I don't know.</p> <p>3 QUESTIONS BY MR. SHKOLNIK:</p> <p>4 Q. Let's go down to the next</p> <p>5 section on Exhibit 7.</p> <p>6 Do you think it's a good idea</p> <p>7 to pay a bonus to a pharmacist to sell</p> <p>8 prescription opioids?</p> <p>9 MR. HILL: Same objections.</p> <p>10 THE WITNESS: I don't know.</p> <p>11 QUESTIONS BY MR. SHKOLNIK:</p> <p>12 Q. I mean, we're not talking</p> <p>13 Pampers. We're not talking household</p> <p>14 products. We're talking addictive opioid</p> <p>15 pills.</p> <p>16 Do you think it's appropriate</p> <p>17 for a company to be paying the pharmacist a</p> <p>18 bonus for that by the pill?</p> <p>19 MR. HILL: Asked and answered</p> <p>20 many times.</p> <p>21 MR. SHKOLNIK: And it will be</p> <p>22 asked again.</p> <p>23 THE WITNESS: I don't know.</p> <p>24 QUESTIONS BY MR. SHKOLNIK:</p> <p>25 Q. Let's go to history of SOM</p>
<p style="text-align: right;">Page 171</p> <p>1 THE WITNESS: I don't know.</p> <p>2 QUESTIONS BY MR. SHKOLNIK:</p> <p>3 Q. We know there was an opioid</p> <p>4 epidemic at least in 2012, according to your</p> <p>5 testimony, correct?</p> <p>6 MR. HILL: Object to the form.</p> <p>7 THE WITNESS: I was aware of an</p> <p>8 opioid epidemic.</p> <p>9 QUESTIONS BY MR. SHKOLNIK:</p> <p>10 Q. At that time?</p> <p>11 A. At that time.</p> <p>12 Q. And do you think getting a</p> <p>13 bonus on how many pills you could sell --</p> <p>14 when I say "pills," opioids. Do you think</p> <p>15 the incentive of getting a bonus for how many</p> <p>16 pills you sell may play a role in whether or</p> <p>17 not you dispense the drug and try to get</p> <p>18 overrides to get more of the drug to sell?</p> <p>19 MR. HILL: Object to the form.</p> <p>20 Foundation. Asked and answered.</p> <p>21 THE WITNESS: I don't know.</p> <p>22 QUESTIONS BY MR. SHKOLNIK:</p> <p>23 Q. Human nature, isn't it? You</p> <p>24 sell more pills, you make more money.</p> <p>25 Wouldn't that be an incentive to many people?</p>	<p style="text-align: right;">Page 173</p> <p>1 daily reporting.</p> <p>2 "Beginning October 2012,</p> <p>3 Cardinal Health has been providing a daily</p> <p>4 list of pharmacy orders that have triggered a</p> <p>5 SOM event from the previous order day. The</p> <p>6 SOM report is reviewed by RX inventory to</p> <p>7 identify any red-flagged Florida pharmacies</p> <p>8 blocked from ordering controlled substances.</p> <p>9 Also identified are any large orders that the</p> <p>10 system generated or manually keyed by the</p> <p>11 pharmacy that are not red-flag locations."</p> <p>12 First of all, do you know what</p> <p>13 a red flag means?</p> <p>14 A. Red flag can mean anything.</p> <p>15 Q. What did it mean in the sense</p> <p>16 of SOM daily reporting when you took over</p> <p>17 integrity in December of 2012?</p> <p>18 A. A red flag could be an order</p> <p>19 that was of interest.</p> <p>20 Q. Did you ever have any dealings</p> <p>21 with Cardinal over their SOM policy and the</p> <p>22 reporting to your company?</p> <p>23 A. Can you rephrase that question?</p> <p>24 Q. Yeah.</p> <p>25 Did you ever have any</p>

44 (Pages 170 to 173)

Highly Confidential - Subject to Further Confidentiality Review

Page 174	Page 176
<p>1 interaction with Cardinal Health in 2012 when 2 you took over -- when you and Tasha took over 3 pharmacy integrity about what their process 4 was when they were receiving orders from your 5 stores? 6 A. I don't know any -- I don't 7 have any information on what Cardinal was 8 doing. 9 Q. Was Cardinal a distributor that 10 was being utilized by the stores at that 11 time? 12 A. Yes, one of many. 13 Q. If Cardinal was the 14 distributor, was the order going through 15 inventory -- inventory management? 16 MR. HILL: Object to the form. 17 Foundation. 18 QUESTIONS BY MR. SHKOLNIK: 19 Q. In that time? 20 A. What time? I'm sorry. 21 Q. In the 2012 time frame before 22 you took over. 23 MR. HILL: Same objections. 24 THE WITNESS: Were orders being 25 transmitted to Cardinal; is that what</p>	<p>1 would refresh your recollection as to what 2 was done when you took over? 3 I mean, it seems like you don't 4 recall a lot of this stuff. I'm just trying 5 to figure out what I should be looking at. 6 MR. HILL: Object to the form. 7 MR. SHKOLNIK: I'll rephrase 8 it. 9 QUESTIONS BY MR. SHKOLNIK: 10 Q. Let's continue looking at this 11 document. 12 It says, "Cardinal Health is 13 providing daily lists of pharmacy orders that 14 have triggered SOM event from the previous 15 order day." 16 Would that be maybe something 17 that refreshes your recollection that 18 Cardinal Health was actually distributing to 19 your pharmacies beginning in October 2012? 20 MR. HILL: Object to the form. 21 THE WITNESS: They may have 22 been dispense -- or distributing, but 23 they -- I can't speculate on the drugs 24 that were flagged. 25</p>
Page 175	Page 177
<p>1 you're asking? 2 QUESTIONS BY MR. SHKOLNIK: 3 Q. No. No. 4 If a store needed -- needed 5 more opioids and they were utilizing Cardinal 6 Health as a distributor, would the order go 7 through pharmacy management, or would it go 8 directly from store to Cardinal back then? 9 MR. HILL: Same objections. 10 THE WITNESS: I can't recall. 11 QUESTIONS BY MR. SHKOLNIK: 12 Q. Were stores receiving 13 distribution from Cardinal and Walgreens 14 during the 2012 time frame? 15 A. I can't recall. 16 Q. Could a store get multiple -- 17 withdraw that. 18 Could stores have multiple 19 sources for opioids when you took over the 20 program? 21 MR. HILL: Object to the form. 22 THE WITNESS: I can't recall. 23 QUESTIONS BY MR. SHKOLNIK: 24 Q. Are there any documents 25 anywhere that would help -- that you think</p>	<p>1 QUESTIONS BY MR. SHKOLNIK: 2 Q. Oh, so this is possibly not 3 related to opioids; is that the issue? 4 A. Yes. 5 Q. Well, it goes on to show -- 6 say -- I'm sorry, it goes on to say, "Also 7 identified are any large orders that the 8 system generated, SIMS, or manually keyed by 9 the pharmacy that are not red-flag 10 locations." 11 Were you aware of red-flag 12 locations in Florida or around the country 13 when you took over? 14 A. Only the locations that were a 15 part of the seizure of the licensure in 16 Florida. 17 Q. "SOM daily report is filtered 18 to identify red-flag Florida stores. These 19 orders are reviewed by RX inventory to 20 determine how they were generated." 21 Would that be an indication 22 that these stores may have been requesting 23 fills or orders directly from Cardinal and 24 not going through inventory management? 25 MR. HILL: Object to the form.</p>

45 (Pages 174 to 177)